Trial Profile
A Phase 1b Trial of Dinaciclib in Combination With Rituximab in Subjects With Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Dinaciclib (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Aug 2013 New source identified and integrated (United Kingdom Clinical Research Network record: 13251).
- 14 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.